Oleg V Tcheremissine
Overview
Explore the profile of Oleg V Tcheremissine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahabaleshwarkar R, Lin D, Joshi K, Fishman J, Blair T, Hetherington T, et al.
J Ment Health Policy Econ
. 2021 Jun;
24(2):47-59.
PMID: 34151777
Background: Schizophrenia is one of 15 major causes of disability worldwide and is responsible for more than USD 150 billion in annual healthcare costs in the United States. Although the...
2.
Mahabaleshwarkar R, Lin D, Fishman J, Blair T, Hetherington T, Palmer P, et al.
Adv Ther
. 2021 Mar;
38(4):1958-1974.
PMID: 33704681
Introduction: Previous evidence demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated the impact of initiating once-monthly paliperidone palmitate (PP1M) on healthcare...
3.
Tokmic F, Hadzikadic M, Cook J, Tcheremissine O
Innov Clin Neurosci
. 2018 Jul;
15(5-6):34-42.
PMID: 30013818
Given the growing public health importance of measuring the change in mental health stigma over time, the goal of this study was to demonstrate the potential for using machine learning...
4.
Tcheremissine O, Rachal J
Innov Clin Neurosci
. 2017 Jun;
14(3-4):11.
PMID: 28584691
No abstract available.
5.
Tcheremissine O, Bestha D
Innov Clin Neurosci
. 2016 Sep;
13(7-8):13-4.
PMID: 27672482
No abstract available.
6.
Tcheremissine O, Rossman W, Castro M, Gardner D
World J Psychiatry
. 2014 Sep;
4(3):49-55.
PMID: 25250221
Tremendous progress has been made in the past decade surrounding the underlying mechanisms and treatment of neuropsychiatric disease. Technological advancements and a broadened research paradigm have contributed to the understanding...
7.
Tcheremissine O, Englert D
Innov Clin Neurosci
. 2013 Dec;
10(9-10):10-1.
PMID: 24307974
No abstract available.
8.
Tcheremissine O, Castro M, Gardner D
Expert Opin Investig Drugs
. 2011 Nov;
21(1):7-14.
PMID: 22059602
Introduction: Schizophrenia is a chronic disorder associated with positive and negative symptoms and wide-ranging deficits in neurocognitive function. Neurocognitive deficits are considered to be the core pathophysiological symptoms of the...
9.
Tcheremissine O, Lieving L
Ther Clin Risk Manag
. 2009 Jun;
5(2):367-79.
PMID: 19536322
Attention-deficit/hyperactivity disorder (ADHD) is the most commonly diagnosed psychiatric disorder in children and adolescents. Symptoms of ADHD often persist beyond childhood and present significant challenges to adults. Pharmacotherapy is a...
10.
Tcheremissine O
Expert Opin Drug Saf
. 2008 Nov;
7(6):739-48.
PMID: 18983220
Background: The abuse and diversion of pharmacological agents with CNS mechanisms of action is an important concern from governmental, regulatory, public health and safety perspectives. In recent years, there have...